ROS-scavenging hydrogels
The ROS-clearing hydrogel GelMA-PVA-TSPBA simulates the in vivo microenvironment, and the problem of sparse number and low homing implantation efficiency in in vitro culture of HSPCs was solved, and the self-renewal ability and biocompatibility of HSPCs were improved, thus achieving the High-efficiency amplification in vitro.
Patent Information
- Application Number
- CN202310611008.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
AI Technical Summary
The existing in vitro culture methods of HSPCs have problems with sparse number and low homing implantation efficiency. It is mainly due to the difference between the 2D culture mode and the microenvironment in vivo, which leads to cells being easily damaged by oxidative stress, and the self-renewal ability is difficult to maintain.
The ROS-scavenging hydrogel GelMA-PVA-TSPBA is used to simulate the microenvironment structure in vivo and has the ability to remove reactive oxygen species. It provides a low ROS environment, which is conducive to the self-renewal and amplification of HSPCs.
By simulating the microenvironment structure in vivo and clearing ROS, the self-renewal ability of HSPCs in vitro is improved, laying the foundation for establishing an in vitro culture system for transplantable HSPCs, and enhancing the biocompatibility and growth ability of cells.
Smart Images

Figure HDA0004252465180000011 
Figure HDA0004252465180000012 
Figure HDA0004252465180000013
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of cell culture, and in particular to a method for culturing hematopoietic stem / progenitor cells using a ROS-scavenging hydrogel. Background Art
[0002] Hematopoietic stem / progenitor cells (HSPCs) are located at the top of the hematopoietic system cascade, with the ability of self-renewal and multi-lineage hematopoietic differentiation. They play an important role in maintaining hematopoietic balance, promoting blood transport, regulating the normal function of immune function and tissue remodeling in the whole body. HSPCs dysfunction may lead to the occurrence of blood system diseases, such as leukemia, lymphoma, etc. Usually, such diseases are mainly treated clinically by HSPCs transplantation, but there are two major bottlenecks for HSPCs used for transplantation treatment: scarcity and low efficiency of homing implantation.
[0003] In order to break through these two major bottlenecks and expand a large number of HSPCs with stemness in vitro so that they can play a stronger hematopoietic reconstitution function in vivo, it is necessary to improve the current HSPCs in vitro culture method. Summary of the invention
[0004] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent.
[0005] At present, the in vitro culture method of HSPCs is mainly based on the two-dimensional (2D) culture model of co-culture of cytokines, small molecule compounds and stromal cells. However, the 2D culture model is quite different from the in vivo bone marrow hematopoietic microenvironment, specifically in terms of cell morphology, polarity, receptor expression, and interaction with the extracellular matrix (ECM). Once HSPCs are separated from the normal physiological conditions in the body, they are susceptible to oxidative stress damage, which increases the level of intracellular reactive oxygen species (ROS), making it difficult to maintain their self-renewal ability and limited their expansion ability.
[0006] In order to improve the above problems, the inventors used new biological materials to culture HSPCs in vitro. Compared with the traditional 2D cell culture system, the 3D culture system is closer to the real microenvironment structure in vivo. Among the many 3D culture biological materials, the inventors found that methacryloyl gelatin (GelMA) can better simulate the biophysical properties of ECM in vitro, provide cells with a mechanical environment similar to that in vivo, and make it possible to simulate the in vivo HSPCs microenvironment. In addition, GelMA hydrogel still retains the arginine-glycine-aspartic acid (RGD) peptide sequence in gelatin that promotes cell adhesion and the target sequence of matrix metalloproteinases (MMPs), which is beneficial to cell adhesion, proliferation and differentiation. Therefore, GelMA hydrogel is a good choice for simulating natural ECM.
[0007] Although GelMA hydrogel can simulate the microenvironment structure in vivo well, it does not have the ability of removing ROS in the microenvironment in vivo. In addition, because GelMA has a good diffusion effect on water-soluble molecules, it cannot wrap compounds such as cytokines for a long time. The inventors complexed polyvinyl alcohol (PVA) with ROS unstable initiator N1-(4-boron benzyl phenyl)-N3-(4-boron phenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diamine (TSPBA) to form a borate bond sensitive to ROS, and then obtained a PVA-TSPBA hydrogel with the ability to respond to ROS. When TSPBA is stimulated by ROS, it is oxidized and hydrolyzed, releasing p-hydroxybenzyl alcohol and tetramethyl propylene diamine, which has the function of removing ROS in the environment and reducing the ROS level in the cell. However, PVA-TSPBA hydrogel does not have cell attachment sites, which is not conducive to adherent cell culture. In order to solve these shortcomings, the inventors considered introducing GelMA into PVA-TSPBA hydrogel. This composite 3D material has good biocompatibility and the ability to remove ROS, and also provides the possibility of loading drugs or cytokines.
[0008] As a new type of 3D in vitro culture material, the ROS-scavenging hydrogel GelMA-PVA-TSPBA provides a low-ROS environment for HSPCs after encapsulating them, which is beneficial for HSPCs to maintain their self-renewal ability in vitro and lays a research foundation for establishing an in vitro culture system that provides a large number of transplantable HSPCs.
[0009] Therefore, in one aspect of the present invention, the present invention proposes a hydrogel. According to an embodiment of the present invention, the hydrogel raw materials include: methacrylated gelatin (GelMA), polyvinyl alcohol (PVA) and N1-(4-boron benzylphenyl)-N3-(4-boron phenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diamine (TSPBA). According to an embodiment of the present invention, the hydrogel not only has good biocompatibility, but also has the ability to remove ROS and reduce the level of ROS in cells, which is beneficial to HSPCs in vitro to maintain self-renewal ability, and lays a research foundation for establishing an in vitro culture system that provides a large number of transplantable HSPCs, and also provides the possibility of loading drugs or cytokines.
[0010] It should be noted that the "methacrylic gelatin (GelMA)" described in the present invention is prepared from methacrylic anhydride (MA) and gelatin, and is a photosensitive biohydrogel material. The material has excellent biocompatibility and can be cured by ultraviolet light or visible light to form a three-dimensional structure suitable for cell growth and differentiation and having a certain strength. The methacrylic gelatin was purchased.
[0011] According to an embodiment of the present invention, the mass concentration of the methacryloyl gelatin in the hydrogel is 5-10% (w / v). Therefore, the hydrogel can have good biocompatibility and the ability to promote cell attachment and growth.
[0012] According to a specific embodiment of the present invention, the mass concentration of the methacryloyl gelatin in the hydrogel is 7.7% (w / v).
[0013] According to an embodiment of the present invention, the mass concentration of the polyvinyl alcohol in the hydrogel is 5-10% (w / v). Therefore, it can be well complexed with TSPBA to form a gel, laying a foundation for the subsequent generation of the hydrogel.
[0014] According to a specific embodiment of the present invention, the mass concentration of the polyvinyl alcohol in the hydrogel is 6.9% (w / v).
[0015] According to an embodiment of the present invention, the mass concentration of N1-(4-boron benzylphenyl)-N3-(4-boron phenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diamidium (TSPBA) in the hydrogel is 0.5-1% (w / v). Therefore, the hydrogel can have the ability to remove ROS and reduce the level of ROS in cells, while promoting cell growth.
[0016] According to a specific embodiment of the present invention, the mass concentration of N1-(4-borobenzylphenyl)-N3-(4-borobenylphenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diamine in the hydrogel is 0.69% (w / v).
[0017] It should be noted that the mass unit in the “mass concentration” described in the present invention is gram (g), and the volume unit is liter (L).
[0018] In another aspect of the present invention, the present invention proposes a method for constructing a hydrogel. According to an embodiment of the present invention, the method includes: performing a first mixing treatment on methacryloyl gelatin (GelMA), polyvinyl alcohol (PVA) and a first PBS solution to obtain a first mixed solution; performing a second mixing treatment on N1-(4-boron benzylphenyl)-N3-(4-boron phenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diamine (TSPBA) and a second PBS solution to obtain a second mixed solution; performing a third mixing treatment on the first mixed solution and the second mixed solution to obtain the hydrogel. According to an embodiment of the present invention, the method for preparing a hydrogel is simple to operate, time-saving and labor-saving, and the cost is not high. In addition, the prepared hydrogel has good biocompatibility and the ability to remove ROS, which is beneficial for HSPCs to maintain self-renewal ability in vitro, and lays a research foundation for establishing an in vitro culture system that provides a large number of transplantable HSPCs.
[0019] According to an embodiment of the present invention, the method for constructing a hydrogel further includes at least one of the following additional technical features:
[0020] According to an embodiment of the present invention, the mass concentration of the methacryloyl gelatin in the first mixed solution is 7-13% (w / v), so that the hydrogel prepared subsequently can be guaranteed to have good biocompatibility and the ability to promote cell attachment and growth.
[0021] According to a specific embodiment of the present invention, the mass concentration of the methacryloyl gelatin in the first mixed solution is 10% (w / v).
[0022] According to an embodiment of the present invention, the mass concentration of the polyvinyl alcohol in the first mixed solution is 6-12% (w / v). Therefore, it can be well complexed with TSPBA to form a gel, which lays a foundation for the subsequent formation of the hydrogel.
[0023] According to a specific embodiment of the present invention, the mass concentration of the polyvinyl alcohol in the first mixed liquid is 9% (w / v).
[0024] According to an embodiment of the present invention, the mass concentration of N1-(4-boron benzylphenyl)-N3-(4-boron phenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diamidium in the second mixed solution is 1-5% (w / v). Therefore, it can be ensured that the hydrogel prepared subsequently has the ability to remove ROS and reduce the level of ROS in cells.
[0025] According to a specific embodiment of the present invention, the mass concentration of N1-(4-borobenzylphenyl)-N3-(4-borobenylphenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diaminium in the second mixed solution is 3% (w / v).
[0026] According to an embodiment of the present invention, the first PBS solution contains phenyl-2,4,6-trimethylbenzoylphosphonic acid lithium, and the mass concentration of phenyl-2,4,6-trimethylbenzoylphosphonic acid lithium in the first PBS solution is 0.1-1% (w / v). The inventors have found through a large number of experiments that when a certain amount of phenyl-2,4,6-trimethylbenzoylphosphonic acid lithium is added to the first PBS solution, the hydrogel prepared subsequently can be stably gelled and has good biocompatibility.
[0027] According to an embodiment of the present invention, the volume ratio of the first mixed liquid to the second mixed liquid is (5-15):(1-5). Within this volume ratio range, the prepared hydrogel can have a better morphology and is not easily deformed.
[0028] According to an embodiment of the present invention, after the first mixing treatment, the method further comprises heating the first mixed solution in a light-proof condition.
[0029] According to an embodiment of the present invention, the heating treatment is performed in a water bath.
[0030] According to an embodiment of the present invention, the temperature of the water bath is 80-90°C.
[0031] According to an embodiment of the present invention, the heating treatment time is 40 to 50 minutes.
[0032] According to an embodiment of the present invention, after the third mixing treatment, the method further includes subjecting the third mixing treatment product to ultraviolet light irradiation treatment.
[0033] According to an embodiment of the present invention, the ultraviolet light irradiation treatment lasts for 45 to 60 seconds.
[0034] In another aspect of the present invention, the present invention provides a hydrogel. According to an embodiment of the present invention, the hydrogel is obtained by the method described above. The hydrogel has good biocompatibility and the ability to remove ROS, which is beneficial for HSPCs to maintain self-renewal ability in vitro, and lays a research foundation for establishing an in vitro culture system that provides a large number of transplantable HSPCs.
[0035] In yet another aspect of the present invention, the present invention provides use of the aforementioned hydrogel in three-dimensional in vitro cell culture.
[0036] It should be noted that all the features and advantages described above for the aforementioned hydrogel are also applicable to this application and will not be described in detail here.
[0037] According to an embodiment of the present invention, the cells are stem cells.
[0038] According to a specific embodiment of the present invention, the stem cells are hematopoietic stem cells or progenitor cells.
[0039] In another aspect of the present invention, the present invention provides a method for in vitro cell expansion. According to an embodiment of the present invention, the cells are cultured in the hydrogel described above. The method can effectively expand the cells and keep the cells in their original morphology and performance.
[0040] According to an embodiment of the present invention, the cells are stem cells.
[0041] According to a specific embodiment of the present invention, the stem cells are hematopoietic stem cells or progenitor cells.
[0042] In another aspect of the present invention, the present invention provides a method for removing reactive oxygen species in cells. According to an embodiment of the present invention, the cells are cultured in the hydrogel described above. The method can effectively remove reactive oxygen species in cells and promote cell growth.
[0043] According to an embodiment of the present invention, the cells are stem cells.
[0044] According to a specific embodiment of the present invention, the stem cells are hematopoietic stem cells or progenitor cells.
[0045] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0047] Figure 1 is to detect the activity of HS-5 cells in GelMA-PVA-TSPBA hydrogel according to an embodiment of the present invention;
[0048] Figure 2 The morphology of HS-5 cells in GelMA-PVA-TSPBA hydrogel was detected according to an embodiment of the present invention;
[0049] Figure 3 : is a representative flow cytometric graph of hematopoietic stem / progenitor cells in products of mouse bone marrow Kit-positive cells under different culture conditions using a flow cytometer according to an embodiment of the present invention;
[0050] Figure 4 The flow cytometer according to the embodiment of the present invention detects the proportion and expansion multiple of hematopoietic stem / progenitor cells in the products of mouse bone marrow Kit-positive cells under different culture conditions;
[0051] Figure 5 This is a representative flow cytometric graph of hematopoietic stem / progenitor cells in the product of mouse bone marrow Kit-positive cells under culture conditions containing trophoblast cells according to an embodiment of the present invention;
[0052] Figure 6 The flow cytometer according to the embodiment of the present invention detects the proportion and expansion multiple of hematopoietic stem / progenitor cells in the product of mouse bone marrow Kit-positive cells under culture conditions containing trophoblast cells;
[0053] Figure 7 is an immunofluorescence image for detecting the activity of umbilical artery endothelial cells (HUAEC) in GelMA-PVA-TSPBA hydrogel according to an embodiment of the present invention;
[0054] Figure 8 It is a statistical graph of detecting the activity of umbilical artery endothelial cells (HUAEC) in GelMA-PVA-TSPBA hydrogel according to an embodiment of the present invention. DETAILED DESCRIPTION
[0055] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention. If no specific techniques or conditions are specified in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used that do not specify the manufacturer are all conventional products that can be obtained commercially.
[0056] Example 1 Construction and biocompatibility testing of GelMA-PVA-TSPBA hydrogel
[0057] (1) Construction of GelMA-PVA-TSPBA hydrogel
[0058] a. Prepare GelMA-PVA hydrogel solution: Dissolve the photoinitiator LAP (phenyl-2,4,6-trimethylbenzoylphosphonate lithium, Engineering For Life, product number EFL-LAP) in PBS solution to prepare 0.25% (w / v) LAP solution. Take the required mass of GelMA (Engineering For Life, product number EFL-GM-60) and PVA (Sigma, product number P8136) and dissolve them in 0.25% (w / v) LAP solution to make the mass concentrations of GelMA and PVA 10% (w / v) and 9% (w / v), respectively. Heat and dissolve in a water bath at 85°C in the dark for 45 minutes, and then immediately filter and sterilize with a 0.22μm sterile needle while hot.
[0059] b. Prepare TSPBA solution: dissolve TSPBA (Xi'an Ruixi Biotechnology Co., Ltd., product number R-TSPBA-1) in PBS solution to obtain a concentration of 3% (w / v) TSPBA, and sterilize by filtration with a 0.22 μm sterile needle.
[0060] c. GelMA-PVA-TSPBA hydrogel solution solidification: The GelMA-PVA hydrogel solution prepared in step a and the TSPBA solution prepared in step b were mixed in a low-adsorption 24-well plate at a volume ratio of 10:3, and irradiated with ultraviolet light for 51 seconds to obtain GelMA-PVA-TSPBA hydrogel.
[0061] (2) Biocompatibility testing of GelMA-PVA-TSPBA hydrogel
[0062] a. Cell inoculation: The cultured bone marrow stromal cells were collected and centrifuged at 1200 rpm / min for 5 minutes using (HS-5) and the supernatant was discarded. The cells were then resuspended in the GelMA-PVA hydrogel solution prepared in step (1) and inoculated with 1×10 6 The cells were inoculated at a density of 1.544 × 10 / mL in a low-adsorption 24-well plate, and the TSPBA solution prepared in step (1) was added and then cured by ultraviolet light. DMEM medium containing 10% fetal bovine serum (FBS) was added and cultured at 37°C and 5% CO2.
[0063] b. Cell activity detection: After 7 days of culture, the GelMA-PVA-TSPBA colloid encapsulating HS-5 cells was transferred to a 6-well plate and stained using a cytotoxicity kit. Calcein and PI dyes were used to stain live and dead cells, respectively.
[0064] c. Cell morphology detection: After 7 days of culture, the GelMA-PVA-TSPBA colloids encapsulating HS-5 cells were transferred to a 6-well plate, and the cytoskeleton and cell nucleus were stained with Phalloidin and DAPI, respectively.
[0065] The experimental results are shown in Figure 1 and Figure 2 The experimental results show that HS-5 maintains high activity in GelMA-PVA-TSPBA hydrogel and has good cell morphology.
[0066] Example 2: Isolation of Mouse Bone Marrow Kit-Positive Cells
[0067] Follow these steps to isolate mouse bone marrow Kit-positive cells:
[0068] C57BL / 6 mice were killed by cervical dislocation, and the femur and tibia were separated. The bone marrow cells were flushed out with PBS containing 2% FBS and 1% double antibody; centrifuged at 400×g for 5 minutes; the supernatant was discarded, and ACK red blood cell lysis buffer was added to lyse the red blood cells; centrifuged at 400×g for 5 minutes; the supernatant was discarded, and the cells were resuspended with PBS containing 2% FBS, and an equal volume of mouse bone marrow lymphocyte separation solution was added; centrifuged at 400×g for 5 minutes at 4°C, the residual lymphocyte separation solution was discarded, and the cells were washed once with PBS containing 2% FBS; the mouse bone marrow cells were divided into 10 7 The cells were resuspended in 80 μL of MACS buffer (Miltenyl Boitec, catalog number 130-091-222, 130-091-376), and 20 μL of CD117 MicroBeads were added and incubated at 4°C for 15 min.
[0069] After the incubation, add 10 ml of PBS containing 2% FBS and mix well. Centrifuge at 400 × g for 5 min. 7 Resuspend the cells in 500 μL of MACS buffer, then install the MS separation column on the magnetic rack, wet the separation column with 1 mL of MACS buffer, slowly add the mouse bone marrow cell suspension along the inner wall of the separation column, avoid bubbles in the process, wait for it to flow out naturally, and then rinse the separation column with 500 μL of MACS buffer for 2 times to rinse the unbound cells out of the separation column;
[0070] The separation column was removed from the magnetic field and placed in a 15 mL centrifuge tube in turn. 3 mL of MACS buffer was used for pressure elution. 5 mL of MACS buffer was added and the cells were washed once by centrifugation at 400 × g for 5 min. The supernatant was discarded, and the cells were resuspended to 1 mL and counted to obtain the primary isolated mouse bone marrow Kit-positive cells (mouse hematopoietic stem / progenitor cells).
[0071] Example 3: In vitro culture of mouse bone marrow Kit-positive cells
[0072] (1) Preparation of GelMA hydrogel solution
[0073] Dissolve the photoinitiator LAP (phenyl-2,4,6-trimethylbenzoylphosphonate lithium, Engineering For Life, product number EFL-LAP) in PBS solution to prepare 0.25% (w / v) LAP solution. Take the required mass of GelMA (Engineering For Life, product number EFL-GM-60) and dissolve it in 0.25% (w / v) LAP solution to make the mass concentration of GelMA 10% (w / v), heat and dissolve it in a water bath at 85°C in the dark for 45 minutes, and then immediately filter and sterilize it while hot with a 0.22μm sterile needle.
[0074] (2) 3D in vitro culture
[0075] The mouse bone marrow Kit-positive cells obtained above were divided into 1×10 6 / mL density was mixed with the GelMA hydrogel solution (GelMA group) prepared above and the GelMA-PVA hydrogel solution (GelMA-PVA group) prepared in Example 1 and inoculated in a low-adsorption 24-well plate. The GelMA group was directly UV-cured, and the GelMA-PVA group was UV-cured after adding the TSPBA solution prepared in Example 1 (the GelMA-PVA hydrogel solution and the TSPBA solution were mixed at a volume ratio of 10:3). The two groups were added with a medium containing 10% FBS, 50ng / mL SCF (stem cell factor), 50ng / mL TPO (thrombopoietin), 50ng / mL IL-3 (interleukin 3), and 50ng / mL FLT3 (FMS-like tyrosine kinase 3) mixed with α-MEM and EGM-2 in equal proportions, respectively, and cultured at 37°C and 5% CO2. During the culture process, the fluid was replenished or replaced every two days. Thus, in vitro expanded mouse bone marrow Kit-positive cells were obtained.
[0076] (3) 2D in vitro culture
[0077] The mouse bone marrow Kit-positive cells obtained above were taken in the same number of cells as those in the 3D in vitro culture, inoculated into a 6-well plate, and a culture medium containing 10% FBS, 50ng / mL SCF (stem cell factor), 50ng / mL TPO (thrombopoietin), 50ng / mL IL-3 (interleukin 3), 50ng / mL FLT3 (FMS-like tyrosine kinase 3) and an equal proportion of α-MEM and EGM-2 was added, and cultured at 37°C and 5% CO2. During the culture process, the fluid was replenished or replaced every two days. Thus, in vitro expanded mouse bone marrow Kit-positive cells were obtained.
[0078] Example 4: Detection of hematopoietic stem / progenitor cell expansion results
[0079] The Kit-positive cells of mouse bone marrow cultured for 7 days were subjected to flow cytometry to detect the expression of surface markers CD45, SCA-1, Kit and CD201. The specific steps are as follows:
[0080] Aspirate the culture medium, add GelMA lysis buffer (Engineering For Life, product number EFL-GM-LS-001) to lyse GelMA and GelMA-PVA-TSPBA colloid, collect cells, put into a 15 ml centrifuge tube, fill with PBS; centrifuge at 400 × g for 5 min; discard the supernatant, fill with PBS again; centrifuge at 400 × g for 5 min again; discard the supernatant, add 100 μL of PBS and transfer to a 1.5 mL EP tube; add 1 μL each of CD45, SCA-1, Kit and CD201 antibodies to each tube of cells, incubate at 4°C for 30 min; centrifuge at 400 × g for 5 min; wash twice with PBS, make up to 200-300 μL, and perform flow cytometry detection.
[0081] The experimental results are shown in Figure 3 and Figure 4 The experimental results show that CD45 + SCA-1 + Kit + CD201 + The number of cells under 3D culture conditions increased compared with that under 2D culture conditions, and the proliferation efficiency was most significant in GelMA-PVA-TSPBA modified hydrogels. Figure 3 BV605, BV421, APC and PE represent different flow cytometry fluorescence channels)
[0082] Example 5: Co-culture of trophoblast cells and mouse bone marrow Kit-positive cells
[0083] The enriched mouse bone marrow Kit-positive cells were labeled with CFSE dye (Sigma, Cat. No. 21888). Bone marrow stromal cells (HS-5), umbilical artery endothelial cells (HUAEC) and human osteoblasts (hFOB1.19) were collected and mixed in a ratio of 1:1 (Kit: (HS-5+HUAEC+hFOB1.19)) and resuspended in the GelMA-PVA hydrogel solution prepared in Example 1, wherein the ratio of HS-5:HUAEC:hFOB1.19 was 1:1:1. The GelMA-PVA mixed solution containing cells was inoculated in a low-adsorption 24-well plate, and the TSPBA solution prepared in Example 1 was added and then cured by ultraviolet light. A medium containing 10% FBS, 50ng / mL SCF, 50ng / mL TPO, 50ng / mL IL-3, and 50ng / mL FLT3 in an equal proportion of α-MEM and EGM-2 was added and cultured at 37°C and 5% CO2. During the culture process, the fluid was replenished or replaced every two days. Thus, in vitro expanded mouse bone marrow Kit-positive cells were obtained.
[0084] Example 6: Detection of hematopoietic stem / progenitor cell expansion results after adding trophoblast cells
[0085] The Kit-positive cells of mouse bone marrow cultured for 7 days were detected by flow cytometry, and the detection indicators were the expression of surface markers CD45, SCA-1, Kit and CD201. The specific steps are as follows:
[0086] Aspirate the culture medium, add GelMA lysis buffer to lyse GelMA-PVA-TSPBA colloid, collect cells, put into 15ml centrifuge tube, fill with PBS; centrifuge at 400×g for 5min, discard the supernatant, fill with PBS again; centrifuge at 400×g for 5min again; discard the supernatant, add 100μL PBS and transfer to 1.5mL EP tube; add 1μL each of CD45, SCA-1, Kit and CD201 antibodies to each tube of cells, incubate at 4℃ for 30min; centrifuge at 400g for 5min; wash twice with PBS, make up to 200-300μL, and perform flow cytometry detection.
[0087] There are many stromal cells in the natural bone marrow microenvironment, which interact with HSPCs and play an important regulatory role in the self-renewal and directional differentiation of HSPCs. Adding stromal cells can better simulate the natural bone marrow microenvironment. The experimental results are shown in Figure 5 and Figure 6 The experimental results show that after adding trophoblast cells, CD45 + SCA-1 + Kit + CD201 + The number of cells increased significantly.
[0088] Comparative Example 8 TSPBA concentration screening
[0089] (1) Construction of GelMA-PVA-TSPBA hydrogel and preparation of extract
[0090] TSPBA was dissolved in PBS solution to prepare TSPBA solutions with concentrations of 3% (w / v), 9% (w / v), and 18% (w / v), and the solutions were sterilized by filtration using a 0.22 μm sterile needle.
[0091] The GelMA-PVA hydrogel solution was prepared as described in Example 1 to obtain a mass concentration of 10% (w / v) GelMA and 9% (w / v) PVA.
[0092] The GelMA-PVA hydrogel solution was mixed with TSPBA solutions of different concentrations at a volume ratio of 10:3 in a low-adsorption 24-well plate and irradiated with UV light for 51 s to prepare three types of hydrogels: 10% GelMA-9% PVA-3% TSPBA, 10% GelMA-9% PVA-9% TSPBA, and 10% GelMA-9% PVA-18% TSPBA. Each sample was then plated with a surface area to extract volume ratio of 2.5 cm 2 / mL standard, immersed in EGM-2 culture medium, and extracted in a 37℃, 5% CO2 incubator for 24h.
[0093] (2) Cell inoculation and activity detection
[0094] a. Cell inoculation: umbilical artery endothelial cells (HUAEC) were centrifuged at 1000 rpm / min for 5 minutes and 3×10 4 The cells were inoculated in a laser confocal cell culture dish and cultured in EGM-2 medium at 37°C, 5% CO2 for 24 h. Then, the original culture medium was discarded and the extracts of three hydrogels, 10% GelMA-9% PVA-3% TSPBA, 10% GelMA-9% PVA-9% TSPBA, and 10% GelMA-9% PVA-18% TSPBA, were added and cultured at 37°C, 5% CO2 for 24 h.
[0095] b. Cell activity detection: After the culture is completed, a cytotoxicity kit is used for staining, and calcein and PI dyes are used to stain live and dead cells respectively.
[0096] The experimental results are as follows Figure 7 and Figure 8As shown in the figure, only when the TSPBA concentration is 3%, the cell activity is good, while when the TSPBA concentration is 9% or 18%, the number of live cells is significantly reduced, the number of dead cells increases, and the cell state is poor, the cell morphology gradually tends to be round, and the endothelial cells are functionally damaged. Therefore, only when the TSPBA concentration is 3%, GelMA-PVA-TSPBA hydrogel can help cell growth without destroying the cell morphology and function.
[0097] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0098] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A hydrogel, characterized in that: The raw materials include: methacrylated gelatin, polyvinyl alcohol and N1-(4-boron benzylphenyl)-N3-(4-boron phenyl)-N1, N1, N3, N3-tetramethylpropane-1, 3-diaminium.
2. The hydrogel according to claim 1, characterized in that The mass concentration of the methacryloyl gelatin in the hydrogel is 5 to 10%; Optionally, the mass concentration of the polyvinyl alcohol in the hydrogel is 5 to 10%; Optionally, the mass concentration of the N1-(4-borobenzylphenyl)-N3-(4-borobenylphenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diaminium in the hydrogel is 0.5-1%.
3. A method for constructing a hydrogel, characterized in that: include: Performing a first mixing process on the methacrylated gelatin, polyvinyl alcohol and the first PBS solution to obtain a first mixed solution; Performing a second mixing treatment on N1-(4-boron benzylphenyl)-N3-(4-boron phenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diaminium and a second PBS solution to obtain a second mixed solution; The first mixed solution and the second mixed solution are subjected to a third mixing process to obtain the hydrogel.
4. The method according to claim 3, characterized in that The mass concentration of the methacryloyl gelatin in the first mixed solution is 7-13%; Optionally, the mass concentration of the polyvinyl alcohol in the first mixed solution is 6 to 12%; Optionally, the mass concentration of the N1-(4-boron benzylphenyl)-N3-(4-boron phenyl)-N1, N1, N3, N3-tetramethylpropane-1,3-diaminium in the second mixed solution is 1 to 5%; Optionally, the first PBS solution contains phenyl-2,4,6-trimethylbenzoyl lithium phosphonate, and the mass concentration of phenyl-2,4,6-trimethylbenzoyl lithium phosphonate in the first PBS solution is 0.1-1%; Optionally, the volume ratio of the first mixed liquid to the second mixed liquid is (5-15):(1-5).
5. The method according to claim 3, characterized in that: After the first mixing treatment, the method further comprises heating the first mixed solution under light-proof conditions; Optionally, the heating treatment is carried out under water bath conditions; Optionally, the temperature of the water bath is 80-90°C; Optionally, the heating treatment time is 40 to 50 minutes.
6. The method according to claim 3, characterized in that After the third mixing treatment, further comprising subjecting the third mixing treatment product to ultraviolet light irradiation treatment; Optionally, the ultraviolet light irradiation treatment time is 45 to 60 seconds.
7. A hydrogel, characterized in that: It is obtained by the method described in any one of 3 to 6.
8. Use of the hydrogel according to claim 1, 2 or 7 in three-dimensional in vitro cell culture; Preferably, the cells are stem cells; More preferably, the stem cells are hematopoietic stem or progenitor cells.
9. A method for in vitro cell expansion, characterized in that: Cultivating the cells in the hydrogel according to claim 1, 2 or 7; Preferably, the cells are stem cells; More preferably, the stem cells are hematopoietic stem or progenitor cells.
10. A method for removing active oxygen in cells, characterized in that: Cultivating the cells in the hydrogel according to claim 1, 2 or 7; Preferably, the cells are stem cells; More preferably, the stem cells are hematopoietic stem or progenitor cells.
